PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from 16 ...
Helmy Eltoukhy, Ph.D., co-founder, chairman and co-chief executive officer of Guardant Health, discusses how sophisticated blood-based technology combined with artificial intelligence is ushering in a ...
Guardant Health grows with Shield blood CRC screening, Quest deal, 50M reach, 335% surge, and FY25 revenue $981M up 33%. Read ...
Multi-year global collaboration will utilize Guardant liquid biopsy portfolio in research and clinical applications and evaluate utility of ctDNA for monitoring therapy response Under the multi-year ...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, ...
Guardant Health is the market leader in liquid Comprehensive Genomic Profiling (CGP) for all solid cancers, and is the only company to offer blood- and tissue-based tests across the entire continuum ...
Powered by Guardant Infinity smart liquid biopsy platform, advanced multiomic test evaluates genomic, epigenomic and RNA-based molecular data First tissue comprehensive genomic profiling test to offer ...
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a strategic collaboration with Pfizer, Inc. (NYSE: PFE), to support the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback